• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined hormonal contraceptives in gene mutation carriers: why not?

作者信息

Grandi Giovanni, Sammarini Margaret, Del Savio Maria Chiara, Toss Angela, Facchinetti Fabio

机构信息

Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy.

Department of Surgery, Medical, Dental and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy.

出版信息

Eur J Contracept Reprod Health Care. 2019 Dec;24(6):417-419. doi: 10.1080/13625187.2019.1647335. Epub 2019 Jul 30.

DOI:10.1080/13625187.2019.1647335
PMID:31361161
Abstract
摘要

相似文献

1
Combined hormonal contraceptives in gene mutation carriers: why not?基因突变携带者使用复方激素避孕药：为何不可？
Eur J Contracept Reprod Health Care. 2019 Dec;24(6):417-419. doi: 10.1080/13625187.2019.1647335. Epub 2019 Jul 30.
2
BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.BRCA1和BRCA2基因变异携带者、口服避孕药的使用与50岁前乳腺癌
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1863-70. doi: 10.1158/1055-9965.EPI-06-0258. Epub 2006 Oct 4.
3
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.口服避孕药与BRCA1和BRCA2基因突变携带者患乳腺癌的风险
J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9. doi: 10.1093/jnci/94.23.1773.
4
[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].[BRCA1和BRCA2乳腺癌的遗传形式对雌激素敏感吗？]
Bull Cancer. 2004 Jul-Aug;91(7-8):583-91.
5
The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.基于蒽环类药物的辅助化疗后，BRCA1和BRCA2突变携带者患心肌病的发生率。
Breast Cancer Res Treat. 2017 Feb;162(1):59-67. doi: 10.1007/s10549-016-4101-8. Epub 2017 Jan 9.
6
Sporadic breast cancer among relatives of BRCA mutation carriers.
Genet Med. 2005 Nov-Dec;7(9):655-6. doi: 10.1097/01.gim.0000187155.63849.85.
7
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.口服避孕药的使用与 BRCA1/2 携带者的乳腺癌或卵巢癌风险：一项荟萃分析。
Eur J Cancer. 2010 Aug;46(12):2275-84. doi: 10.1016/j.ejca.2010.04.018. Epub 2010 May 27.
8
Risk reduction works for BRCA mutation carriers--with heavy costs.降低风险对携带BRCA基因突变者有效——但成本高昂。
J Natl Cancer Inst. 2005 Jul 20;97(14):1032-3. doi: 10.1093/jnci/dji228.
9
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].[与BRCA 1和BRCA2基因相关的乳腺癌的分子基础：特征与靶向治疗]
Lijec Vjesn. 2010 Jan-Feb;132(1-2):34-7.
10
Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.关于：口服避孕药与BRCA1和BRCA2基因突变携带者患乳腺癌的风险
J Natl Cancer Inst. 2003 Jul 2;95(13):1010-1; author reply 1012-3. doi: 10.1093/jnci/95.13.1010.

引用本文的文献

1
Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome.患有遗传性乳腺癌和/或卵巢癌综合征的年轻健康女性生殖潜力降低。
Commun Med (Lond). 2025 Mar 8;5(1):70. doi: 10.1038/s43856-025-00788-9.
2
Contraception During Perimenopause: Practical Guidance.围绝经期避孕：实用指南
Int J Womens Health. 2022 Jul 15;14:913-929. doi: 10.2147/IJWH.S288070. eCollection 2022.
3
Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.除BRCA外的遗传性乳腺癌和/或卵巢癌综合征的二级预防
J Oncol. 2020 Jul 14;2020:6384190. doi: 10.1155/2020/6384190. eCollection 2020.
4
BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.意大利一组无家族史的管腔型早发性和三阴性乳腺癌患者的BRCA检测率：生物学何时超越家谱学。
Cancers (Basel). 2020 May 15;12(5):1252. doi: 10.3390/cancers12051252.